Overview
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Eligibility
Key Inclusion Criteria:
- Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
- Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
- Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
Key Exclusion Criteria:
- Prior islet cell transplant, organ transplant (other than kidney transplant) or cell therapy
- Participants had greater than (>)1 kidney transplant procedure
Other protocol defined Inclusion/Exclusion criteria may apply.